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Adoptive immunotherapy with chimeric antigen receptor
(CAR) transduced T lymphocytes has shown promising
results in both pediatric and adult B cell malignancies.
Nevertheless, both CAR-based and antibody-based anti-
CD19 therapies, e.g. blinatumomab, have seen treatment
failures attributed to the loss of CD19 or an epitope of
CD19 on the surface of the malignant B cell. It may be
possible to overcome antigen escape by targeting two
tumor antigens simultaneously, i.e. CD19 and CD20
using a tandem construct with two scFv-based CAR
binding domains. Lentiviral vectors encoding chimeric
antigen receptors comprised of anti-CD19 and anti-
CD20 targeting domains expressed alone or in tandem
were transduced into T cells from healthy donors to gen-
erate the corresponding CAR19, CAR20, CAR19_20
(CD19 scFv more distal to the T cell plasma membrane)
and CAR20_19 T cells (CD20 scFv distal). The trans-
duced T cells were 50-70% CAR positive as determined
by protein L flow cytometric analysis. Expression of CAR
proteins of the expected molecular weight was confirmed
by Western blot analysis of transduced T cells. When
CAR-transduced T cells were combined with CD19
+CD20+ Raji target cells, but not CD19-CD20- K562 cells,
all four CAR T cell types demonstrated comparable effi-
cient killing of leukemia targets (E:T ratio >2), and
target-dependent induction of IFN-g, as measured in co-
culture supernatants by ELISA.
We then began a series of in vitro co-culture experi-
ments where we used very low E:T ratios to examine
the potential for CAR-induced antigen loss on surviving
leukemia cells. All CAR-T cells expressing an anti-CD19
scFv induced rapid loss of CD19 surface expression.
In contrast, the CD20 surface marker was less prone to
down-regulation by CAR-T cells expressing anti-CD20
scFv. Upon flow cytometric analysis of surviving leuke-
mia cells on day 5, CD19 expression was reduced to 3%,
48%, 73%, 90% and 93% of control when co-cultured
with CAR T cells expressing CAR19_20, CAR20_19,
CAR19, CAR20, and control T cells, respectively. Similar
results were seen when experiments were of longer,
7 days, or shorter, 1 day, duration. In conclusion, tandem
CAR T cells are as effective as single CAR19 or CAR20
T cells in leukemia cell killing. Importantly, dual scFv-
expressing CARs are more potent in preventing tumor
antigen escape via target antigen down-regulation.
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